Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.69 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TYMP | P19971 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL13062153 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL13320592 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL6748953 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL18249508 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL12964365 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL1738548 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL16707275 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL13012212 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL6933022 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL29669658 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240023528-A1 | ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-01-25 | — | — | US | disclosed |
| US-11827880-B2 | Therapeutic editing | SHAPE THERAPEUTICS INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230371483-A1 | METHODS AND COMPOSITIONS FOR SEXING AND STERILIZATION IN DROSOPHILA SUZUKII AND AEDES AEGYPTI | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-23 | — | — | US | disclosed |
| US-20230183689-A1 | Compositions and Methods for Genome Editing | SHAPE THERAPEUTICS INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230174977-A1 | ENGINEERED CIRCULAR POLYNUCLEOTIDES | SHAPE THERAPEUTICS INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230139474-A1 | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20230044119-A1 | Therapeutic Editing | SHAPE THERAPEUTICS INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220186226-A1 | RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES | UNIV CALIFORNIA (US) | 2022-06-16 | — | — | US | disclosed |
| US-11339441-B2 | Profiling chemically modified DNA/RNA units for disease and cancer diagnosis | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220033818-A1 | OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES | HOFFMANN-LA ROCHE INC. | 2022-02-03 | — | — | US | disclosed |
| US-20130281362-A1 | ANTIVIRAL AGENT | "IVY PHARM" LIMITED LIABILITY COMPANY (RU) | 2013-10-24 | — | — | US | disclosed |
| US-20130281362-A1 | ANTIVIRAL AGENT | "IVY PHARM" LIMITED LIABILITY COMPANY (RU) | 2013-10-24 | — | — | US | disclosed |
| EP-2407474-B1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INST MATERIA MEDICA CAMS (CN) | 2013-08-14 | — | — | EP | disclosed |
| US-8435962-B2 | Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-05-07 | — | — | US | disclosed |
| US-8435962-B2 | Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-05-07 | — | — | US | disclosed |
| US-20120053143-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-03-01 | — | — | US | disclosed |
| US-20120053143-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-03-01 | — | — | US | disclosed |
| US-20100190737-A1 | COMPOSITIONS COMPRISING INOSINE AND OROTIC ACID AND METHODS OF USE THEREOF FOR THE TREATMENT OF CERTAIN HEART CONDITIONS AND ENHANCEMENT OF WORK CAPACITY | NUTRITIONAL RESEARCH GROUP LLC (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190737-A1 | COMPOSITIONS COMPRISING INOSINE AND OROTIC ACID AND METHODS OF USE THEREOF FOR THE TREATMENT OF CERTAIN HEART CONDITIONS AND ENHANCEMENT OF WORK CAPACITY | NUTRITIONAL RESEARCH GROUP LLC (US) | 2010-07-29 | — | — | US | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | PAX8 954/4885P2RX3 52/4885HPGD 381/4885 |
| US-20240023528-A1 | ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE | ALPG, RNGTT, NASP | PAX8 2962/4885P2RX3 4051/4885HPGD 2606/4885 |
| US-20120053143-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | ADORA3, ADORA2A, ADORA1 | PAX8 3798/4885P2RX3 172/4885HPGD 1673/4885 |
| US-20220186226-A1 | RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES | UPF1, RNASE1, TARBP1 | PAX8 760/4885P2RX3 4147/4885HPGD 4077/4885 |
| US-20230139474-A1 | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | UPF1, TARBP1, RNASE1 | PAX8 1576/4885P2RX3 4360/4885HPGD 4551/4885 |
| US-20130281362-A1 | ANTIVIRAL AGENT | ITPA, GMPS, GGCT | PAX8 3833/4885P2RX3 3922/4885HPGD 1951/4885 |
| US-20100190737-A1 | COMPOSITIONS COMPRISING INOSINE AND OROTIC ACID AND METHODS OF USE THEREOF FOR THE TREATMENT OF CERTAIN HEART CONDITIONS AND ENHANCEMENT OF WORK CAPACITY | TNNI3, TNNC1, TNNT2 | PAX8 3956/4885P2RX3 4515/4885HPGD 290/4885 |
| US-20230044119-A1 | Therapeutic Editing | DCLRE1B, NSUN3, MTREX | PAX8 1705/4885P2RX3 2748/4885HPGD 4376/4885 |
| US-11827880-B2 | Therapeutic editing | DCLRE1B, NSUN3, MTREX | PAX8 1705/4885P2RX3 2748/4885HPGD 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.